Noble Financial reaffirmed their buy rating on shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) in a report issued on Monday morning, StockTargetPrices.com reports.

Separately, Zacks Investment Research upgraded shares of VBI Vaccines, Inc. – from a hold rating to a buy rating and set a $4.75 price target for the company in a research report on Saturday, May 6th.

Shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) traded down 0.591% during mid-day trading on Monday, hitting $4.205. 77,181 shares of the stock were exchanged. The company’s 50-day moving average is $4.70 and its 200-day moving average is $4.13. VBI Vaccines, Inc. – has a 1-year low of $2.75 and a 1-year high of $6.60. The firm’s market cap is $168.30 million.

TRADEMARK VIOLATION NOTICE: “VBI Vaccines, Inc. -‘s (VBIV) “Buy” Rating Reaffirmed at Noble Financial” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/05/19/vbi-vaccines-inc-s-vbiv-buy-rating-reaffirmed-at-noble-financial.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VBIV. Goldman Sachs Group Inc. purchased a new position in VBI Vaccines, Inc. – during the first quarter valued at $383,000. KCG Holdings Inc. purchased a new position in VBI Vaccines, Inc. – during the first quarter valued at $512,000. Morgan Stanley raised its position in VBI Vaccines, Inc. – by 28,153.6% in the first quarter. Morgan Stanley now owns 62,723 shares of the biopharmaceutical company’s stock valued at $344,000 after buying an additional 62,501 shares during the last quarter. Geode Capital Management LLC raised its position in VBI Vaccines, Inc. – by 31.0% in the first quarter. Geode Capital Management LLC now owns 22,468 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 5,317 shares during the last quarter. Finally, EAM Investors LLC purchased a new position in VBI Vaccines, Inc. – during the first quarter valued at $414,000. 22.11% of the stock is currently owned by institutional investors and hedge funds.

VBI Vaccines, Inc. – Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

5 Day Chart for NASDAQ:VBIV

Stock Target Prices

Receive News & Stock Ratings for VBI Vaccines Inc. - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. - and related stocks with our FREE daily email newsletter.